Skip to main content
CRISPR Therapeutics AG logo

CRISPR Therapeutics AG — Investor Relations & Filings

Ticker · CRSP ISIN · CH0334081137 LEI · 506700O6IRRIQLT3W370 US Manufacturing
Open in API
Filings indexed 823 across all filing types
Latest filing 2017-12-21 Board/Management Inform…
Country CH Switzerland
Listing US CRSP

About CRISPR Therapeutics AG

https://crisprtx.com/

CRISPR Therapeutics AG is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. The company leverages this technology to make precise, directed changes to genomic DNA. As a pioneer in the field, CRISPR Therapeutics has established a diverse portfolio of therapeutic programs across several disease areas, including hemoglobinopathies (such as sickle cell disease and beta-thalassemia), immuno-oncology, regenerative medicine, and cardiovascular disease. The company was one of the first to advance a CRISPR-based therapy into clinical trials and receive regulatory approval, aiming to create potentially curative treatments for patients.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated December 20, 2017, for CRISPR Therapeutics AG. The main content details the resignation of a director and chairman, Dr. Anthony Coles, and the appointment of Dr. Rodger Novak as chairman. It also discusses the compensatory arrangements for Dr. Novak as president. The document includes employment and advisory agreements as exhibits and a press release. There is no financial data or report content such as earnings, annual or quarterly financial statements, or audit information. The focus is on changes in the board of directors and senior management. Therefore, the document fits the category of Board/Management Information (MANG).
2017-12-21 English
FORM 4 SUBMISSION
Director's Dealing
2017-12-19 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement, specifically a Joint Development and Commercialization Agreement between CRISPR Therapeutics and Vertex Pharmaceuticals. It includes details about governance, commercialization, financial terms, termination rights, and amendments to a prior collaboration agreement. There are no financial statements or quarterly/yearly financial results presented, nor is this a transcript, proxy, or governance document. The document is not an announcement of a report publication but a regulatory filing disclosing a significant corporate event. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (8292 characters) and detailed content support this classification with high confidence.
2017-12-18 English
FORM 4 SUBMISSION
Director's Dealing
2017-12-07 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text indicates it is a short filing (2677 characters) reporting the submission of a Clinical Trial Application and includes a press release as an exhibit. There are no financial statements or detailed financial data presented. The document is primarily an announcement of an event rather than a financial report or detailed management discussion. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. Given the nature of the filing and its content, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2017-12-07 English
SC 13D/A
Major Shareholding Notification
2017-12-06 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.